CBT reported Q2 fiscal 2026 results on May 5 that beat on every line — yet short sellers used the rally to add, not reduce. That tension sits at the heart of this week's setup.
Cabot's headline numbers were clean. Adjusted EPS came in at $1.61 against a $1.46 estimate, a 15-cent beat. Revenue of $904 million nudged past the $900 million consensus. Management reaffirmed full-year adjusted EPS guidance of $6.00–$6.50, which brackets the $6.23 current estimate. The stock responded well, closing Wednesday up 4.1% to $78.93 and adding a further 2.7% on the week. The Q2 print arrived in good company — peer EMN gained nearly 8% on the week, and MTX added 8.5%.
Short positioning tells a more complicated story. SI climbed to 5.9% of the free float — its highest reading in the six-week window covered by this data. That puts the absolute short position at roughly 3.03 million shares, up 17.5% from a month ago. The week-on-week rise is modest at 1.5%, but the trend since early April has been consistent and one-directional. Shorts were rebuilding ahead of earnings and have not yet covered in its wake. The borrowing market offers little deterrent: cost to borrow remains negligible at 0.46%, and borrow availability, while tightening, is still not at stress levels — the lending pool is far from exhausted. This is patient, low-friction short positioning, not a distressed squeeze setup. Availability has risen alongside the short build, suggesting the supply of lendable shares is broadly matching demand.
Options traders, by contrast, have shifted clearly bullish. The put/call ratio dropped to 0.31 on Tuesday, well below its 20-day average of 0.36, and sits near the lower end of its recent range. For context, the PCR ran as high as 0.48 through much of April — the move lower happened sharply in the last week as the earnings date approached. That rotation from hedged to outright long exposure reflects confidence in the print, which the numbers subsequently justified. The z-score of -0.55 confirms the PCR is below-average but not at an extreme — call buyers are active, not euphoric.
On the Street, the most recent move belongs to Mizuho's John Roberts, who raised his target to $80 from $75 on May 6 while keeping a Neutral rating. That target aligns closely with the mean analyst estimate of $78.80 — barely above the current price of $78.93. The market has, in effect, already priced in where the neutral consensus sits. The broader analyst picture is split: Mizuho and UBS both hold Neutral ratings with targets in the $80–$81 range, while JPMorgan remains at Underweight. The JPMorgan bear case has been persistent — the firm has held an Underweight rating through multiple price-target revisions — and it represents the clearest pushback on the valuation story. At a trailing P/E of 12.3x and EV/EBITDA of 7.1x, Cabot is not expensively priced for a specialty chemicals name, and the EV/EBIT factor score ranks in the 86th percentile of the universe. Whether the multiple re-rates from here depends on how durable the earnings beat proves to be. EPS momentum scores sit in the 53rd percentile over 30 days, and the 90-day reading is a softer 34th — a signal that estimate revisions have been constructive but not aggressive.
Institutionally, the ownership base is stable and well-anchored. BlackRock holds 12.7% and Vanguard 11.4%. American Century added 384,000 shares in the most recently reported period, the most visible fresh buying among named holders. FMR (Fidelity) added over 726,000 shares as recently as February. Those are meaningful flows for a stock of this size and suggest active managers were positioning ahead of the earnings recovery. Insider data is stale — the most recent trades on record are from November 2025 — so that angle offers nothing actionable this week.
What to watch next: with no upcoming earnings date currently in the calendar and the stock trading essentially at the neutral consensus target, the debate between the active manager inflows, the persistent short build, and the JPMorgan bear case will likely be played out through incremental estimate revisions and any commentary around tariff exposure for a carbon-black and specialty-fluids manufacturer operating in global commodity chemicals.
See the live data behind this article on ORTEX.
Open CBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
